Menu

PubMed Commons to Stop Accepting Comments

The venue for post-publication peer review was not getting enough participation.

Feb 5, 2018
Kerry Grens

WIKIMEDIA, CANJIE6As of February 15, PubMed Commons, a site where verified users can discuss one another’s papers, will stop taking reader comments. The National Center for Biotechnology Information (NCBI) announced last week (February 1) that only 6,000 papers out of the 28 million in PubMed’s database had received any reviews, prompting the agency to end its efforts into the program.

“While many worthwhile comments were made through the service during its 4 years of operation, [the National Institutes of Health] has decided that the low level of participation does not warrant continued investment in the project, particularly given the availability of other commenting venues,” NCBI says in the statement.

PubPeer, for instance, has had much more success. Retraction Watch reports that the site hosts comments on nearly 70,000 scientific papers, and the team there credits that in part to greater a permissiveness on its site than PubMed Commons offered.

“Compared to PubPeer, PubMed Commons forbade anonymity,” PubPeer leaders say in a statement to Retraction Watch. “We have always felt that many users, particularly those with the most significant criticisms, prefer to comment anonymously in order to avoid any risk of reprisals.”

Although users will be able to access archived comments after March 2, they won’t be readily visible, a concern that psychiatrist Alexander Tsai of Massachusetts General Hospital voiced to Nature. He had posted a correction to one of his own papers on PubMed Commons when the journal took no action, and if readers land upon the paper from PubMed or the journal’s website, they won’t be alerted to the errors. “It does concern me,” he tells Nature.

June 2019

Living with Bacteria

Can pathogens be converted to commensals?

Marketplace

Sponsored Product Updates

Gyros Protein Technologies introduces Gyrolab E. coli HCP Kit for automated impurity analysis of biotherapeutics
Gyros Protein Technologies introduces Gyrolab E. coli HCP Kit for automated impurity analysis of biotherapeutics
Ready-to-use immunoassay kit increases analytical output and productivity in bioprocess workflows. Kit developed as part of licensing and supply agreement with Cygnus Technologies
IDT launches ultra-high performance CRISPR Cas12a enzyme
IDT launches ultra-high performance CRISPR Cas12a enzyme
IDT’s new CRISPR Cas12a (Cpf1) Ultra enzyme can target new sites within the genome and with greater efficiency
Implen Launches New NanoPhotometer N120: The High Throughput Champion!
Implen Launches New NanoPhotometer N120: The High Throughput Champion!
Implen GmbH is excited to announce the release of the NanoPhotometer® N120, an absorbance based UV/VIS Multi Channel Spectrophotometer.
StemExpress Announces Release of New Frozen Leukopak® to Advance Research
StemExpress Announces Release of New Frozen Leukopak® to Advance Research
To continue to provide new products and services to further advance medical research around the world, today, StemExpress announced the release of their Frozen Leukopak®.